Celltrion Healthcare is hosting "Global IBD Homecoming Day 2023 (Homecoming)," a five-day event from November 14 to 18, to educate key healthcare professionals from around the world about the competitiveness of Celltrion Group's inflammatory bowel disease (IBD) therapies.
Celltrion Healthcare is hosting the Homecoming event by inviting key opinion leaders (KOLs) from around the world, including Europe, the Americas and Asia, to Korea to promote its products and share the latest medical trends and prescribing practices at home and abroad. This year's event was attended by approximately 40 key IBD physicians from 11 countries, including Canada, Australia, and the Czech Republic.
In a marketing session on the first day of the event, Celltrion Healthcare introduced product-specific features and real-world data for Remsima SC (U.S. trade name ZYMFENTRA), the world's first and only infliximab SC formulation, and Yuflyma (adalimumab), which was recently approved as a new drug in the United States.
Attendees particularly focused on the competitive advantage of Remsima SC during the subsequent medical session, which included an in-depth discussion of Remsima SC dose escalation and monotherapy-related efficacy and safety data from a global Phase 3 post-hoc study.
In addition, Celltrion Healthcare provided a tour of Celltrion Plant 2 and the Global Biotechnology Research Center, explaining the current status of drug development and production processes, and introduced the competitiveness of Celltrion Group, which is developing into a leading global integrated biotechnology company, to enhance the confidence of medical staff.
On the second day, November 15, Celltrion Healthcare held a meeting with Korean medical staff at the Gastroenterology Department of Asan Medical Center in Seoul, Korea, where speakers and attendees exchanged views on IBD-related treatment trends at a global level, as well as patient cases experienced in the real world of medicine, which generated great interest and response.
On November 16, the company will attend "Korea Digestive Disease Week (KDDW) 2023" at the Grand Walkerhill in Seoul to exchange the latest medical information with medical experts and officials from around the world.
